SrasV1, PubMed, Checkpoint, bibRecord, 002524

SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.

Identifieur interne : 002524 ( PubMed/Checkpoint ); précédent : 002523; suivant : 002525

SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.

Auteurs : Patrick C Y. Woo [Hong Kong] ; Susanna K P. Lau ; Hoi-Wah Tsoi ; Zhi-Wei Chen ; Beatrice H L. Wong ; Linqi Zhang ; Jim K H. Chan ; Lei-Po Wong ; Wei He ; Chi Ma ; Kwok-Hung Chan ; David D. Ho ; Kwok-Yung Yuen

Source :

Vaccine [ 0264-410X ] ; 2005.

RBID : pubmed:15993989

Descripteurs français

English descriptors

KwdEn :
- Administration, Oral, Animals, Antibodies, Viral (blood), Antibodies, Viral (immunology), Bacterial Vaccines (administration & dosage), Bacterial Vaccines (immunology), Escherichia coli Proteins, Immunization Schedule, Immunization, Secondary, Immunoglobulin G (blood), Injections, Intramuscular, Injections, Intraperitoneal, Interferon-gamma (analysis), Interleukin-4 (analysis), Male, Membrane Glycoproteins (administration & dosage), Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Mice, Mice, Inbred BALB C, Models, Animal, Neutralization Tests, SARS Virus (immunology), Severe Acute Respiratory Syndrome (prevention & control), Spike Glycoprotein, Coronavirus, Vaccines, DNA (administration & dosage), Vaccines, DNA (immunology), Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (immunology), Viral Envelope Proteins (administration & dosage), Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology).
MESH :
- chemical , administration & dosage : Bacterial Vaccines, Membrane Glycoproteins, Vaccines, DNA, Vaccines, Synthetic, Viral Envelope Proteins.
- chemical , analysis : Interferon-gamma, Interleukin-4.
- chemical , blood : Antibodies, Viral, Immunoglobulin G.
- chemical , genetics : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , immunology : Antibodies, Viral, Bacterial Vaccines, Membrane Glycoproteins, Vaccines, DNA, Vaccines, Synthetic, Viral Envelope Proteins.
- immunology : SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- Administration, Oral, Animals, Escherichia coli Proteins, Immunization Schedule, Immunization, Secondary, Injections, Intramuscular, Injections, Intraperitoneal, Male, Mice, Mice, Inbred BALB C, Models, Animal, Neutralization Tests, Spike Glycoprotein, Coronavirus.

Abstract

Different forms of SARS coronavirus (SARS-CoV) spike protein-based vaccines for generation of neutralizing antibody response against SARS-CoV were compared using a mouse model. High IgG levels were detected in mice immunized with intraperitoneal (i.p.) recombinant spike polypeptide generated by Escherichia coli (S-peptide), mice primed with intramuscular (i.m.) tPA-optimize800 DNA vaccine (tPA-S-DNA) and boosted with i.p. S-peptide, mice primed with i.m. CTLA4HingeSARS800 DNA vaccine (CTLA4-S-DNA) and boosted with i.p. S-peptide, mice primed with oral live-attenuated Salmonella typhimurium (Salmonella-S-DNA-control) and boosted with i.p. S-peptide, mice primed with oral live-attenuated S. typhimurium that contained tPA-optimize800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide, and mice primed with oral live-attenuated S. typhimurium that contained CTLA4HingeSARS800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide. No statistical significant difference was observed among the Th1/Th2 index among these six groups of mice with high IgG levels. Sera of all six mice immunized with i.p. S-peptide, i.m. DNA vaccine control and oral Salmonella-S-DNA-control showed no neutralizing antibody against SARS-CoV. Sera of the mice immunized with i.m. tPA-S-DNA, i.m. CTLA4-S-DNA, oral Salmonella-S-DNA-control boosted with i.p. S-peptide, oral Salmonella-tPA-S-DNA, oral Salmonella-tPA-S-DNA boosted with i.p S-peptide, oral Salmonella-CTLA4-S-DNA and oral Salmonella-CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of <1:20-1:160. Sera of all the mice immunized with i.m. tPA-S-DNA boosted with i.p. S-peptide and i.m. CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of >or=1:1280. The present observation may have major practical value, such as immunization of civet cats, since production of recombinant proteins from E. coli is far less expensive than production of recombinant proteins using eukaryotic systems.

DOI: 10.1016/j.vaccine.2005.05.023
PubMed: 15993989

Affiliations:

Hong Kong

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002659
to stream PubMed, to step Curation: 002659

Links to Exploration step

pubmed:15993989

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.</title>
<author><name sortKey="Woo, Patrick C Y" sort="Woo, Patrick C Y" uniqKey="Woo P" first="Patrick C Y" last="Woo">Patrick C Y. Woo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, The University of Hong Kong, Room 423, University Pathology Building, Queen Mary Hospital, Hong Kong.</nlm:affiliation>
<country xml:lang="fr">Hong Kong</country>
<wicri:regionArea>Department of Microbiology, The University of Hong Kong, Room 423, University Pathology Building, Queen Mary Hospital</wicri:regionArea>
<wicri:noRegion>Queen Mary Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lau, Susanna K P" sort="Lau, Susanna K P" uniqKey="Lau S" first="Susanna K P" last="Lau">Susanna K P. Lau</name>
</author>
<author><name sortKey="Tsoi, Hoi Wah" sort="Tsoi, Hoi Wah" uniqKey="Tsoi H" first="Hoi-Wah" last="Tsoi">Hoi-Wah Tsoi</name>
</author>
<author><name sortKey="Chen, Zhi Wei" sort="Chen, Zhi Wei" uniqKey="Chen Z" first="Zhi-Wei" last="Chen">Zhi-Wei Chen</name>
</author>
<author><name sortKey="Wong, Beatrice H L" sort="Wong, Beatrice H L" uniqKey="Wong B" first="Beatrice H L" last="Wong">Beatrice H L. Wong</name>
</author>
<author><name sortKey="Zhang, Linqi" sort="Zhang, Linqi" uniqKey="Zhang L" first="Linqi" last="Zhang">Linqi Zhang</name>
</author>
<author><name sortKey="Chan, Jim K H" sort="Chan, Jim K H" uniqKey="Chan J" first="Jim K H" last="Chan">Jim K H. Chan</name>
</author>
<author><name sortKey="Wong, Lei Po" sort="Wong, Lei Po" uniqKey="Wong L" first="Lei-Po" last="Wong">Lei-Po Wong</name>
</author>
<author><name sortKey="He, Wei" sort="He, Wei" uniqKey="He W" first="Wei" last="He">Wei He</name>
</author>
<author><name sortKey="Ma, Chi" sort="Ma, Chi" uniqKey="Ma C" first="Chi" last="Ma">Chi Ma</name>
</author>
<author><name sortKey="Chan, Kwok Hung" sort="Chan, Kwok Hung" uniqKey="Chan K" first="Kwok-Hung" last="Chan">Kwok-Hung Chan</name>
</author>
<author><name sortKey="Ho, David D" sort="Ho, David D" uniqKey="Ho D" first="David D" last="Ho">David D. Ho</name>
</author>
<author><name sortKey="Yuen, Kwok Yung" sort="Yuen, Kwok Yung" uniqKey="Yuen K" first="Kwok-Yung" last="Yuen">Kwok-Yung Yuen</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:15993989</idno>
<idno type="pmid">15993989</idno>
<idno type="doi">10.1016/j.vaccine.2005.05.023</idno>
<idno type="wicri:Area/PubMed/Corpus">002659</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002659</idno>
<idno type="wicri:Area/PubMed/Curation">002659</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002659</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002524</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002524</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.</title>
<author><name sortKey="Woo, Patrick C Y" sort="Woo, Patrick C Y" uniqKey="Woo P" first="Patrick C Y" last="Woo">Patrick C Y. Woo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, The University of Hong Kong, Room 423, University Pathology Building, Queen Mary Hospital, Hong Kong.</nlm:affiliation>
<country xml:lang="fr">Hong Kong</country>
<wicri:regionArea>Department of Microbiology, The University of Hong Kong, Room 423, University Pathology Building, Queen Mary Hospital</wicri:regionArea>
<wicri:noRegion>Queen Mary Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lau, Susanna K P" sort="Lau, Susanna K P" uniqKey="Lau S" first="Susanna K P" last="Lau">Susanna K P. Lau</name>
</author>
<author><name sortKey="Tsoi, Hoi Wah" sort="Tsoi, Hoi Wah" uniqKey="Tsoi H" first="Hoi-Wah" last="Tsoi">Hoi-Wah Tsoi</name>
</author>
<author><name sortKey="Chen, Zhi Wei" sort="Chen, Zhi Wei" uniqKey="Chen Z" first="Zhi-Wei" last="Chen">Zhi-Wei Chen</name>
</author>
<author><name sortKey="Wong, Beatrice H L" sort="Wong, Beatrice H L" uniqKey="Wong B" first="Beatrice H L" last="Wong">Beatrice H L. Wong</name>
</author>
<author><name sortKey="Zhang, Linqi" sort="Zhang, Linqi" uniqKey="Zhang L" first="Linqi" last="Zhang">Linqi Zhang</name>
</author>
<author><name sortKey="Chan, Jim K H" sort="Chan, Jim K H" uniqKey="Chan J" first="Jim K H" last="Chan">Jim K H. Chan</name>
</author>
<author><name sortKey="Wong, Lei Po" sort="Wong, Lei Po" uniqKey="Wong L" first="Lei-Po" last="Wong">Lei-Po Wong</name>
</author>
<author><name sortKey="He, Wei" sort="He, Wei" uniqKey="He W" first="Wei" last="He">Wei He</name>
</author>
<author><name sortKey="Ma, Chi" sort="Ma, Chi" uniqKey="Ma C" first="Chi" last="Ma">Chi Ma</name>
</author>
<author><name sortKey="Chan, Kwok Hung" sort="Chan, Kwok Hung" uniqKey="Chan K" first="Kwok-Hung" last="Chan">Kwok-Hung Chan</name>
</author>
<author><name sortKey="Ho, David D" sort="Ho, David D" uniqKey="Ho D" first="David D" last="Ho">David D. Ho</name>
</author>
<author><name sortKey="Yuen, Kwok Yung" sort="Yuen, Kwok Yung" uniqKey="Yuen K" first="Kwok-Yung" last="Yuen">Kwok-Yung Yuen</name>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term>
<term>Animals</term>
<term>Antibodies, Viral (blood)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Bacterial Vaccines (administration & dosage)</term>
<term>Bacterial Vaccines (immunology)</term>
<term>Escherichia coli Proteins</term>
<term>Immunization Schedule</term>
<term>Immunization, Secondary</term>
<term>Immunoglobulin G (blood)</term>
<term>Injections, Intramuscular</term>
<term>Injections, Intraperitoneal</term>
<term>Interferon-gamma (analysis)</term>
<term>Interleukin-4 (analysis)</term>
<term>Male</term>
<term>Membrane Glycoproteins (administration & dosage)</term>
<term>Membrane Glycoproteins (genetics)</term>
<term>Membrane Glycoproteins (immunology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Models, Animal</term>
<term>Neutralization Tests</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (prevention & control)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Vaccines, DNA (administration & dosage)</term>
<term>Vaccines, DNA (immunology)</term>
<term>Vaccines, Synthetic (administration & dosage)</term>
<term>Vaccines, Synthetic (immunology)</term>
<term>Viral Envelope Proteins (administration & dosage)</term>
<term>Viral Envelope Proteins (genetics)</term>
<term>Viral Envelope Proteins (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie orale</term>
<term>Animaux</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps antiviraux (sang)</term>
<term>Calendrier vaccinal</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires (administration et posologie)</term>
<term>Glycoprotéines membranaires (génétique)</term>
<term>Glycoprotéines membranaires (immunologie)</term>
<term>Immunoglobuline G (sang)</term>
<term>Injections musculaires</term>
<term>Injections péritoneales</term>
<term>Interféron gamma (analyse)</term>
<term>Interleukine-4 (analyse)</term>
<term>Modèles animaux</term>
<term>Mâle</term>
<term>Protéines Escherichia coli</term>
<term>Protéines de l'enveloppe virale (administration et posologie)</term>
<term>Protéines de l'enveloppe virale (génétique)</term>
<term>Protéines de l'enveloppe virale (immunologie)</term>
<term>Rappel de vaccin</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Tests de neutralisation</term>
<term>Vaccins antibactériens (administration et posologie)</term>
<term>Vaccins antibactériens (immunologie)</term>
<term>Vaccins synthétiques (administration et posologie)</term>
<term>Vaccins synthétiques (immunologie)</term>
<term>Vaccins à ADN (administration et posologie)</term>
<term>Vaccins à ADN (immunologie)</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bacterial Vaccines</term>
<term>Membrane Glycoproteins</term>
<term>Vaccines, DNA</term>
<term>Vaccines, Synthetic</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Interferon-gamma</term>
<term>Interleukin-4</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin G</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Bacterial Vaccines</term>
<term>Membrane Glycoproteins</term>
<term>Vaccines, DNA</term>
<term>Vaccines, Synthetic</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Vaccins antibactériens</term>
<term>Vaccins synthétiques</term>
<term>Vaccins à ADN</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Interféron gamma</term>
<term>Interleukine-4</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Vaccins antibactériens</term>
<term>Vaccins synthétiques</term>
<term>Vaccins à ADN</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Immunoglobuline G</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Animals</term>
<term>Escherichia coli Proteins</term>
<term>Immunization Schedule</term>
<term>Immunization, Secondary</term>
<term>Injections, Intramuscular</term>
<term>Injections, Intraperitoneal</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Models, Animal</term>
<term>Neutralization Tests</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Administration par voie orale</term>
<term>Animaux</term>
<term>Calendrier vaccinal</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Injections musculaires</term>
<term>Injections péritoneales</term>
<term>Modèles animaux</term>
<term>Mâle</term>
<term>Protéines Escherichia coli</term>
<term>Rappel de vaccin</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Tests de neutralisation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Different forms of SARS coronavirus (SARS-CoV) spike protein-based vaccines for generation of neutralizing antibody response against SARS-CoV were compared using a mouse model. High IgG levels were detected in mice immunized with intraperitoneal (i.p.) recombinant spike polypeptide generated by Escherichia coli (S-peptide), mice primed with intramuscular (i.m.) tPA-optimize800 DNA vaccine (tPA-S-DNA) and boosted with i.p. S-peptide, mice primed with i.m. CTLA4HingeSARS800 DNA vaccine (CTLA4-S-DNA) and boosted with i.p. S-peptide, mice primed with oral live-attenuated Salmonella typhimurium (Salmonella-S-DNA-control) and boosted with i.p. S-peptide, mice primed with oral live-attenuated S. typhimurium that contained tPA-optimize800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide, and mice primed with oral live-attenuated S. typhimurium that contained CTLA4HingeSARS800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide. No statistical significant difference was observed among the Th1/Th2 index among these six groups of mice with high IgG levels. Sera of all six mice immunized with i.p. S-peptide, i.m. DNA vaccine control and oral Salmonella-S-DNA-control showed no neutralizing antibody against SARS-CoV. Sera of the mice immunized with i.m. tPA-S-DNA, i.m. CTLA4-S-DNA, oral Salmonella-S-DNA-control boosted with i.p. S-peptide, oral Salmonella-tPA-S-DNA, oral Salmonella-tPA-S-DNA boosted with i.p S-peptide, oral Salmonella-CTLA4-S-DNA and oral Salmonella-CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of <1:20-1:160. Sera of all the mice immunized with i.m. tPA-S-DNA boosted with i.p. S-peptide and i.m. CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of >or=1:1280. The present observation may have major practical value, such as immunization of civet cats, since production of recombinant proteins from E. coli is far less expensive than production of recombinant proteins using eukaryotic systems.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15993989</PMID>
<DateCompleted><Year>2005</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0264-410X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>23</Volume>
<Issue>42</Issue>
<PubDate><Year>2005</Year>
<Month>Oct</Month>
<Day>10</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.</ArticleTitle>
<Pagination><MedlinePgn>4959-68</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Different forms of SARS coronavirus (SARS-CoV) spike protein-based vaccines for generation of neutralizing antibody response against SARS-CoV were compared using a mouse model. High IgG levels were detected in mice immunized with intraperitoneal (i.p.) recombinant spike polypeptide generated by Escherichia coli (S-peptide), mice primed with intramuscular (i.m.) tPA-optimize800 DNA vaccine (tPA-S-DNA) and boosted with i.p. S-peptide, mice primed with i.m. CTLA4HingeSARS800 DNA vaccine (CTLA4-S-DNA) and boosted with i.p. S-peptide, mice primed with oral live-attenuated Salmonella typhimurium (Salmonella-S-DNA-control) and boosted with i.p. S-peptide, mice primed with oral live-attenuated S. typhimurium that contained tPA-optimize800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide, and mice primed with oral live-attenuated S. typhimurium that contained CTLA4HingeSARS800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide. No statistical significant difference was observed among the Th1/Th2 index among these six groups of mice with high IgG levels. Sera of all six mice immunized with i.p. S-peptide, i.m. DNA vaccine control and oral Salmonella-S-DNA-control showed no neutralizing antibody against SARS-CoV. Sera of the mice immunized with i.m. tPA-S-DNA, i.m. CTLA4-S-DNA, oral Salmonella-S-DNA-control boosted with i.p. S-peptide, oral Salmonella-tPA-S-DNA, oral Salmonella-tPA-S-DNA boosted with i.p S-peptide, oral Salmonella-CTLA4-S-DNA and oral Salmonella-CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of <1:20-1:160. Sera of all the mice immunized with i.m. tPA-S-DNA boosted with i.p. S-peptide and i.m. CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of >or=1:1280. The present observation may have major practical value, such as immunization of civet cats, since production of recombinant proteins from E. coli is far less expensive than production of recombinant proteins using eukaryotic systems.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Woo</LastName>
<ForeName>Patrick C Y</ForeName>
<Initials>PC</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology, The University of Hong Kong, Room 423, University Pathology Building, Queen Mary Hospital, Hong Kong.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lau</LastName>
<ForeName>Susanna K P</ForeName>
<Initials>SK</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tsoi</LastName>
<ForeName>Hoi-Wah</ForeName>
<Initials>HW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Zhi-Wei</ForeName>
<Initials>ZW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wong</LastName>
<ForeName>Beatrice H L</ForeName>
<Initials>BH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Linqi</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chan</LastName>
<ForeName>Jim K H</ForeName>
<Initials>JK</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wong</LastName>
<ForeName>Lei-Po</ForeName>
<Initials>LP</Initials>
</Author>
<Author ValidYN="Y"><LastName>He</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ma</LastName>
<ForeName>Chi</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chan</LastName>
<ForeName>Kwok-Hung</ForeName>
<Initials>KH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ho</LastName>
<ForeName>David D</ForeName>
<Initials>DD</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yuen</LastName>
<ForeName>Kwok-Yung</ForeName>
<Initials>KY</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001428">Bacterial Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D029968">Escherichia coli Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>207137-56-2</RegistryNumber>
<NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001428" MajorTopicYN="N">Bacterial Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D029968" MajorTopicYN="N">Escherichia coli Proteins</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007273" MajorTopicYN="N">Injections, Intramuscular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007274" MajorTopicYN="N">Injections, Intraperitoneal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year>
<Month>12</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2005</Year>
<Month>05</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2005</Year>
<Month>05</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>7</Month>
<Day>5</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>11</Month>
<Day>11</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>7</Month>
<Day>5</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15993989</ArticleId>
<ArticleId IdType="pii">S0264-410X(05)00545-1</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2005.05.023</ArticleId>
<ArticleId IdType="pmc">PMC7115571</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Mar 19;315(4):1134-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14985131</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 2004 Jan 30;279(5):3197-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14670965</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2001 Nov;75(22):10991-1001</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11602739</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 May;78(9):4638-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15078946</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2001 Oct 12;20(1-2):140-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11567758</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Eur J Immunol. 2002 Nov;32(11):3294-304</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12555675</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2004 Sep;10(9):1558-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15498156</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Dec 6;362(9399):1895-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14667748</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Crit Rev Clin Lab Sci. 2004;41(1):1-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15077722</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Virol. 2004 Jul;73(3):338-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15170626</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2139-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15220038</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2122-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15220033</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Clin Microbiol. 2004 Jul;42(7):2884-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15243033</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2002 Jul 26;20(23-24):2878-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12126898</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 2004 Oct 8;576(1-2):174-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15474033</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Jul;78(13):6938-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15194770</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2001 Apr 6;19(20-22):2945-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11282206</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Clin Microbiol. 2004 Dec;42(12):5885-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15583332</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15642942</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Med. 2004 Aug;10(8):871-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15247913</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 1981 May 21;291(5812):238-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7015147</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Clin Microbiol. 2004 May;42(5):2306-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15131220</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunol Lett. 2004 Apr 15;92(3):237-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15081618</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Diagn Lab Immunol. 2004 Jul;11(4):665-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15242938</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>DNA Cell Biol. 2004 Jun;23(6):391-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15231072</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1992 Feb;66(2):956-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1309922</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2000 Sep 1;165(5):2850-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10946318</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Clin Virol. 2004 Sep;31(1):69-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15288617</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2004 Mar 13;363(9412):841-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15031027</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Oct;78(19):10328-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15367599</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Hong Kong</li>
</country>
</list>
<tree><noCountry><name sortKey="Chan, Jim K H" sort="Chan, Jim K H" uniqKey="Chan J" first="Jim K H" last="Chan">Jim K H. Chan</name>
<name sortKey="Chan, Kwok Hung" sort="Chan, Kwok Hung" uniqKey="Chan K" first="Kwok-Hung" last="Chan">Kwok-Hung Chan</name>
<name sortKey="Chen, Zhi Wei" sort="Chen, Zhi Wei" uniqKey="Chen Z" first="Zhi-Wei" last="Chen">Zhi-Wei Chen</name>
<name sortKey="He, Wei" sort="He, Wei" uniqKey="He W" first="Wei" last="He">Wei He</name>
<name sortKey="Ho, David D" sort="Ho, David D" uniqKey="Ho D" first="David D" last="Ho">David D. Ho</name>
<name sortKey="Lau, Susanna K P" sort="Lau, Susanna K P" uniqKey="Lau S" first="Susanna K P" last="Lau">Susanna K P. Lau</name>
<name sortKey="Ma, Chi" sort="Ma, Chi" uniqKey="Ma C" first="Chi" last="Ma">Chi Ma</name>
<name sortKey="Tsoi, Hoi Wah" sort="Tsoi, Hoi Wah" uniqKey="Tsoi H" first="Hoi-Wah" last="Tsoi">Hoi-Wah Tsoi</name>
<name sortKey="Wong, Beatrice H L" sort="Wong, Beatrice H L" uniqKey="Wong B" first="Beatrice H L" last="Wong">Beatrice H L. Wong</name>
<name sortKey="Wong, Lei Po" sort="Wong, Lei Po" uniqKey="Wong L" first="Lei-Po" last="Wong">Lei-Po Wong</name>
<name sortKey="Yuen, Kwok Yung" sort="Yuen, Kwok Yung" uniqKey="Yuen K" first="Kwok-Yung" last="Yuen">Kwok-Yung Yuen</name>
<name sortKey="Zhang, Linqi" sort="Zhang, Linqi" uniqKey="Zhang L" first="Linqi" last="Zhang">Linqi Zhang</name>
</noCountry>
<country name="Hong Kong"><noRegion><name sortKey="Woo, Patrick C Y" sort="Woo, Patrick C Y" uniqKey="Woo P" first="Patrick C Y" last="Woo">Patrick C Y. Woo</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002524 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002524 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:15993989
   |texte=   SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:15993989" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.

SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki